Tests suspended due to the illness of the vaccinated volunteer have been resumed. This is reported on the website of the Anglo-Swedish pharmaceutical company AstraZeneca.
“Clinical trials of the coronavirus vaccine AZD1222 conducted by AstraZeneca and Oxford have been resumed in the UK after confirmation of safety by the Drug Regulatory Authority,” it was reported.
We remind that the tests were suspended due to a neurological symptom in a patient from Great Britain. Earlier in July, clinical trials for the vaccine were also suspended after one volunteer was diagnosed with multiple sclerosis, but further research showed that it was not related to the vaccine.
The third phase of the vaccine trial, which AstraZeneca is developing together with scientists from Oxford University, began in the USA in late August, with 30,000 adult volunteers participating in the tests.